Loading...

Shu Mei Kato

Title(s)Assistant Clinical Professor, Medicine
SchoolHealth Sciences
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Mardinian K, Okamura R, Kato S, Kurzrock R. Temporal and spatial effects and survival outcomes associated with concordance between tissue and blood KRAS alterations in the pan-cancer setting. Int J Cancer. 2019 Jun 14. PMID: 31199507.
      View in: PubMed
    2. Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R. Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study. Nat Med. 2019 05; 25(5):744-750. PMID: 31011206.
      View in: PubMed
    3. Goodman AM, Kato S, Chattopadhyay R, Okamura R, Saunders IM, Montesion M, Frampton GM, Miller VA, Daniels GA, Kurzrock R. Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness. Cancer Immunol Res. 2019 Jun; 7(6):866-873. PMID: 31003990.
      View in: PubMed
    4. Kato S, Schwaederlé MC, Fanta PT, Okamura R, Leichman L, Lippman SM, Lanman RB, Raymond VM, Talasaz A, Kurzrock R. Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival. JCO Precis Oncol. 2019; 3. PMID: 31032472.
      View in: PubMed
    5. Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R. Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. JCO Precis Oncol. 2019; 3. PMID: 31058253.
      View in: PubMed
    6. Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis Oncol. 2018; 2018. PMID: 30637364.
      View in: PubMed
    7. Kato S, Kurzrock R. An avatar for precision cancer therapy. Nat Biotechnol. 2018 11 09; 36(11):1053-1055. PMID: 30412185.
      View in: PubMed
    8. Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, Sicklick JK, Fanta PT, Lippman SM, Kurzrock R. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma. Clin Cancer Res. 2018 Dec 15; 24(24):6248-6256. PMID: 30348637.
      View in: PubMed
    9. Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. JAMA Oncol. 2018 Sep 01; 4(9):1237-1244. PMID: 29902298.
      View in: PubMed
    10. Choi MY, Kato S, Wang HY, Lin JH, Lanman RB, Kurzrock R. JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. Cancer Biol Ther. 2018 08 03; 19(8):664-668. PMID: 29565699.
      View in: PubMed
    11. Kato S, Ross JS, Gay L, Dayyani F, Roszik J, Subbiah V, Kurzrock R. Analysis of MDM2 Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. JCO Precis Oncol. 2018; 2018. PMID: 30148248.
      View in: PubMed
    12. Goodman AM, Kato S, Cohen PR, Boichard A, Frampton G, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies. Oncoimmunology. 2018; 7(3):e1404217. PMID: 29399405.
      View in: PubMed
    13. Patel M, Kato SM, Kurzrock R. Molecular Tumor Boards: Realizing Precision Oncology Therapy. Clin Pharmacol Ther. 2018 02; 103(2):206-209. PMID: 29134641.
      View in: PubMed
    14. Kato S, Kurasaki K, Ikeda S, Kurzrock R. Rare Tumor Clinic: The University of California San Diego Moores Cancer Center Experience with a Precision Therapy Approach. Oncologist. 2018 02; 23(2):171-178. PMID: 29038235.
      View in: PubMed
    15. Kato S, Kurzrock R. Genomics of Immunotherapy-Associated Hyperprogressors-Response. Clin Cancer Res. 2017 10 15; 23(20):6376. PMID: 29030333.
      View in: PubMed
    16. Seguin L, Camargo MF, Wettersten HI, Kato S, Desgrosellier JS, von Schalscha T, Elliott KC, Cosset E, Lesperance J, Weis SM, Cheresh DA. Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. Cancer Discov. 2017 12; 7(12):1464-1479. PMID: 28893801.
      View in: PubMed
    17. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017 11; 16(11):2598-2608. PMID: 28835386.
      View in: PubMed
    18. Schwaederle M, Chattopadhyay R, Kato S, Fanta PT, Banks KC, Choi IS, Piccioni DE, Ikeda S, Talasaz A, Lanman RB, Bazhenova L, Kurzrock R. Genomic Alterations in Circulating Tumor DNA from Diverse Cancer Patients Identified by Next-Generation Sequencing. Cancer Res. 2017 10 01; 77(19):5419-5427. PMID: 28807936.
      View in: PubMed
    19. Cohen PR, Kato S, Goodman AM, Ikeda S, Kurzrock R. Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease. Int J Mol Sci. 2017 Jul 31; 18(8). PMID: 28788102.
      View in: PubMed
    20. Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman SM, Lanman RB, Kurzrock R. Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. Cancer Res. 2017 08 15; 77(16):4238-4246. PMID: 28642281.
      View in: PubMed
    21. Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, Weihe E, Kurzrock R. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. Oncologist. 2017 06; 22(6):631-637. PMID: 28550027.
      View in: PubMed
    22. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res. 2017 Aug 01; 23(15):4242-4250. PMID: 28351930.
      View in: PubMed
    23. Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. Clin Cancer Res. 2017 04 15; 23(8):1988-1997. PMID: 27683183.
      View in: PubMed
    24. Kato S, Tomson BN, Buys TP, Elkin SK, Carter JL, Kurzrock R. Genomic Landscape of Malignant Mesotheliomas. Mol Cancer Ther. 2016 10; 15(10):2498-2507. PMID: 27507853.
      View in: PubMed
    25. Kato S, Lippman SM, Flaherty KT, Kurzrock R. The Conundrum of Genetic "Drivers" in Benign Conditions. J Natl Cancer Inst. 2016 08; 108(8). PMID: 27059373.
      View in: PubMed
    26. Desgrosellier JS, Lesperance J, Seguin L, Gozo M, Kato S, Franovic A, Yebra M, Shattil SJ, Cheresh DA. Integrin avß3 drives slug activation and stemness in the pregnant and neoplastic mammary gland. Dev Cell. 2014 Aug 11; 30(3):295-308. PMID: 25117682.
      View in: PubMed
    27. Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM, Cheresh DA. An integrin ß3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014 May; 16(5):457-68. PMID: 24747441.
      View in: PubMed
    28. Lau SK, Shields DJ, Murphy EA, Desgrosellier JS, Anand S, Huang M, Kato S, Lim ST, Weis SM, Stupack DG, Schlaepfer DD, Cheresh DA. EGFR-mediated carcinoma cell metastasis mediated by integrin avß5 depends on activation of c-Src and cleavage of MUC1. PLoS One. 2012; 7(5):e36753. PMID: 22586492.
      View in: PubMed